Kodiak Sciences Inc. (FRA:K27)

Market Cap	2.12B +362.7%
Revenue (ttm)	n/a
Net Income	-211.82M
EPS	-3.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	33.33
Previous Close	31.44
Day's Range	33.33 - 33.33
52-Week Range	7.21 - 39.74
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: K27

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error